Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains #39;lumpy#39;
http://dlvr.it/StcTr5
http://dlvr.it/StcTr5
